Alzamend Neuro, Inc. — Director's Dealing 2021

Sep 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2021-09-13

Reporting Person: McGrath Lynne Fahey (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-13	Common Stock	M	2778	—	Acquired	2778	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-13	Restricted Stock Grant	$	M	2778	Disposed	2024-09-13	Common Stock (2778)	Direct

Footnotes

F1: Represents the vesting of restricted stock.

F2: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc.

F3: The restricted stock grant vests in 36 equal monthly installments commencing on September 13, 2021.